Seres qui­et­ly dis­clos­es it has once again al­tered plans in ul­cer­a­tive col­i­tis

A month af­ter an­oth­er set­back in its plans to treat ul­cer­a­tive col­i­tis, Seres Ther­a­peu­tics qui­et­ly dis­closed it will not move for­ward with a Phase Ib tri­al.

The move, dis­closed in an SEC fil­ing Wednes­day, puts Seres in a predica­ment as the Cam­bridge, MA biotech failed with one po­ten­tial UC drug, SER-287, last Ju­ly, and again with an­oth­er ex­per­i­men­tal drug last month.

That sec­ond at­tempt, with SER-301, was safe to pro­ceed to the place­bo-con­trolled sec­ond co­hort in a Phase Ib tri­al even though out­come da­ta from the 15 pa­tients in­di­cat­ed none of them had achieved clin­i­cal re­mis­sion af­ter 10 weeks of treat­ment, Seres said on March 1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER